Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
- 16 October 1982
- Vol. 285 (6348) , 1069-1071
- https://doi.org/10.1136/bmj.285.6348.1069
Abstract
The selective 5-hydroxytryptamine2-(5-HT2)-receptor-blocking agent ketanserin was given in a dose of 10 mg intravenously to nine patients with Raynaud's phenomenon. The effect on blood flow was assessed by photopletysmography and measurments of skin temperature. Digital blood flow and skin temperature increased significantly after ketanserin injection, whereas the placebo (saline 9 g/l) had no such effect. This study suggests that ketanserin may be useful in the treatment of Raynaud's phenomenon.Keywords
This publication has 9 references indexed in Scilit:
- Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.BMJ, 1982
- Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit; effect of ketanserin (R 41 468)European Journal of Pharmacology, 1982
- Raynaud syndromeSeminars in Arthritis and Rheumatism, 1981
- Plasma exchange and platelet function in Raynaud's phenomenonThrombosis Research, 1980
- Pathophysiology of Raynaud's DiseaseArchives of internal medicine (1960), 1979
- Pathophysiology of Raynaud's diseaseArchives of internal medicine (1960), 1979
- Vasospastic diseases: A reviewProgress in Cardiovascular Diseases, 1975